Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On February 3, 2025, Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, sold 11,855 shares of common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at prices ranging from $3.46 to $3.56, with a weighted average price of $3.4672.
- Following the transaction, Klee directly owns 3,164,933 shares of Amylyx Pharmaceuticals.
- The sale was automatic and not at the discretion of the reporting person.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes, which is a neutral event.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to sell shares to cover tax obligations related to stock-based compensation.
Stakeholder Impact
- The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of transaction: Justin B. Klee sold shares of Amylyx Pharmaceuticals. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.